Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Monotherapy in Relapsed/Refractory CLL (VENICE I)
NCT02756611Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by AbbVie Inc. Primary endpoint: Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy at 48 weeks. Started Jun 2016; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02756611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756611.